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Background: Lymph node metastasis is one of the most important prognostic factors for extra-hepatic bile duct
carcinoma (ExHBDC). Extra capsular lymph node involvement (ExCLNI) is the extension of cancer cells through the
nodal capsule into the perinodal fatty tissue. The prognostic impact of ExCLNI has been shown to be significant
mainly in head and neck malignancies. Recently, the prognostic impacts of ExCLNI have evaluated in
gastrointestinal malignancies. However no data is available regarding the incidence and prognostic significance of
extra-capsular lymph node involvement (ExCLNI) in resectable ExHBDCs. The aim of the present study is first to
evaluate the incidence of ExCLNI in surgically-treated ExHBDCs and second, to determine the prognostic impact of
ExCLNI in patients with surgically-treated ExHBDCs.
Methods: A total of 228 patients (110 cases of hilar cholangiocarcinoma and 118 cases of distal
cholangiocarcinoma) with surgically-treated ExHBDCs were included in this retrospective study. ExCLNI was defined
as the extension of cancer cells through the nodal capsule into the perinodal fatty tissue. The existence of ExCLNI
and its prognostic value were analyzed as a subgroup of lymph node metastasis.
Results: ExCLNI was detected in only 22% of patients with lymph node metastasis of surgically-treated ExHBDC.
The presence of ExCLNI correlated with distal cholangiocarcinoma (p= 0.002). On univariate analysis for survival,
perineural invasion, vascular invasion, histological grade, and lymph node metastasis were statistically significant
factors. On multivariate analysis, only lymph node metastasis was identified as a significant independent prognostic
factor in patients with resectable ExHBDC. Subgroups of lymph node metastasis including the presence of ExCLNI,
location of lymph node metastasis, and the number of lymph node metastasis had no statistically significant impact
on survival.
Conclusion: ExCLNI was present in only 22% of the LNM (7% of overall patients) in patients with surgical treated
ExHBDCs. And ExCLNI would have no impact on the survival of patients with surgically-treated ExHBDCs.
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Extra-hepatic bile duct cancers (ExHBDCs) continue to
be one of the most difficult cancers to manage in terms of
staging and radical resection. Despite this fact, preopera-
tive diagnosis, management, and operative strategy have
improved. The 5-year survival rate still ranges from 22%
to 40% [1-11]. Regional and para-aortic lymph nodes are
frequently involved in ExHBDCs. Lymph node metastasis
(LNM) is still one of the most important prognostic
factors, although extended lymphadenectomy provides
survival benefits in selected patients with ExHBDCs [6-8,11-
13]. Recently, several investigators have shown that the
subcategories of LNM such as location of the LNM, the
number of LNMs, and the metastatic lymph node ratio
(LNR) were significant prognostic factors [6,11,14-16].
Extra capsular lymph node involvement (ExCLNI) is
the extension of cancer cells through the nodal capsule
into the perinodal fatty tissue. The prognostic impact of
ExCLNI has been shown to be significant mainly in head
and neck malignancies. Recent studies have evaluated
the prognostic value of ExCLNI in other gastrointestinal
malignancies such as esophageal, colon, and gastric
cancer, adenocarcinoma of the ampulla of Vater, and
pancreatic carcinoma [17-22].
Several authors have stated that the presence of
ExCLNI has a prognostic impact based on the following
rationale:
a) ExCLNI could reflect the invasiveness and
aggressiveness of the primary tumor [23,24] andTable 1 Clinicopathological features of 228 cases of extra hep
Clinicopathological characteristics (N= 228)
Age(years) >70
Gender Male/Female
Surgical procedure Major hepatectomy
P.D
P.D with major hepatectomy
Extra hepatic bile duct resection
pT Factor T1-2
T3-4







Microscopic margin status Positive/Negative
Clinicopathological characteristics of patients in this study. pT: 7th classification of Ab) ExCLNI could be one of many patterns of cancer
dissemination [23].
In our best knowledge, no data are available on incidence
and the prognostic significance of ExCLNI in resectable
ExHBDCs [23].
The aim of the present study was to first evaluate the
incidence of ExCLNI in surgically treated ExHBDCs,
and second, to determine the prognostic impact of
ExCLNI (including other subgroups of LNM) in patients
with surgically treated ExHBDCs.
Methods
Patients
Curative resections were performed on 139 patients with
ExHBDCs at the Second Department of Surgery, Hok-
kaido University Hospital in Japan from December 1999
to November 2007. An additional 89 patients with
ExHBDCs, who underwent resection at Teine-Keijinkai
Hospital, Japan from January 1997 to November 2007,
were also included. A total of 152 men and 76 women
were included in this study. The median age was 70 (range
20 to 85). There were 110 cases of hilar cholangiocarci-
noma and 118 cases of distal cholangiocarcinoma. Thus, a
total of 228 patients with ExHBDCs were included in this
report. Patients who underwent an exploratory laparot-
omy, or were diagnosed with gallbladder cancer, adenocar-
cinoma of the ampulla of Vater, or intra hepatic bile duct
cancer in the postoperative period were excluded. Clinico-
pathologic features of patients are shown in Table 1.atic cholangiocarcinoma
Tumor location

















JCC pathological T factor P.D: Pancreaticoduodenectomy.
Figure 1 A lymph node with intra-capsular tumor involvement
embedded in perinodal fat tissue is shown on the left side
(upper: low power field and lower: high power field). An
adenocarcinoma extending through the capsule into the perinodal
fat tissue is shown on the right (upper: low power field and lower:
high power field).
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(TNM) classification criteria according to the American
Joint Committee on Cancer (AJCC), 7th edition [25].
Classifications of lymph node groups according to loca-
tion of the LNM in the present study were classified
according to the 5th edition of Japanese General Rules
for Classification of Biliary Tract Carcinoma currently
used in Japan[26]. This classification system was used to
define the topographic relations of lymph nodes to sur-
rounding structure. For example, lymph node posterior
to the portal vein (12p) is defined as group 1 lymph
node (N1) in hilar cholangiocarcinoma, but the same
lymph node was defined as group 2 lymph node (N2) in
inferior cholangiocarcinoma (See reference [26]).
Operative procedure and adjuvant therapy
The operative criteria and procedure for ExHBDCs were
described in previous reports [1,27-29]. Some of the
patients with T4 (AJCC), whose disease had spread to
the main or bilateral branches of the portal vein, were
considered unrespectable by many surgeons, but were
candidates for resection in our institutes [1,29].
Patients with hilar cholangiocarcinoma were mainly
treated by major hepatectomy with skeletonization of the
portal vein and hepatic artery, and with nodal clearance
around the head of the pancreas. All hepatectomy
included a caudate lobectomy. Distal cholangiocarcinoma
were mainly treated by pancreaticoduodenectomy
(SSPPD) with en-bloc resection of the primary tumor and
regional lymph nodes of the hepatoduodenal ligament.
Skeletonization of the portal vein and the hepatic artery
was included in this procedure as well. An extra hepatic
bile duct resection was performed for selected patients
with liver dysfunction or other complications. No defini-
tive chemotherapy or radiation was added after surgery.
Multiple resections were performed including 90 cases
of major hepatectomy (31 cases of left and 52 cases of
right hepatectomy, 2 cases of left and 5 cases of right tri-
segmentectomy), 95 cases of pancreaticoduodenectomy
(including 4 cases of caudate lobe resection), 13 cases of
pancreaticoduodenectomy with major hepatectomy, and
29 cases of extra-hepatic duct resection (Table 1).
Pathological diagnosis and analysis
Our pathological diagnosis protocol and analysis for
ExHBDCs were based on prior studies [12,13,30]. Lymph
nodes were counted and measured with a slide gauge.
All surgically dissected lymph nodes were examined
pathologically for metastatic foci. For each patient with
LNM, all available hematoxylin and eosin stain slides of
lymph nodes were re-evaluated on a double-headed
microscope by three investigators (MM, TN, and KK)
until a consensus was reached. All investigators were
blinded to survival data.The following data were collected for the resected
specimens: tumor differentiation, perineural invasion,
lymph node status, portal vein and hepatic artery inva-
sion (vascular invasion), and resection margin status.
ExCLNI was defined as the extension of cancer cells
through the nodal capsule into the perinodal fatty tis-
sue (Figure 1). We used lymphatic endothelial marker
(D2-40) and Elastica-Masson stain, when we found a
difficulty to distinguish lymphatic invasion and venous
invasion from ExCLNI. Cases in which the cancer
extended into afferent and efferent structures such as
lymphatic or blood vessels were strictly excluded.
Statistical analysis
Statistical calculations were performed using Dr SPSS-II
(SPSS, Chicago, Illinois, USA). The Chi-square, Fisher’s
exact, and Mann–Whitney U tests were used as appro-
priate. Cumulative survival after surgery was calculated
using the Kaplan-Meier method. The log-rank test was
used to compare cumulative survival. Cox proportional
regression hazard model was used for multivariate ana-




Median total lymph nodes counts resected were 14 in our
presented study. There were 79 patients with LNM. There
were 41 cases of hilar cholangiocarcinoma and 38 cases
of distal cholangiocarcinoma with LNM, respectively.
Median number of LNM were 2 (range 1–8) in hilar
cholangiocarcinoma, and 2 (range 1–6) in distal cholan-
giocarcinoma, respectively. Among 79 patients, there
Table 3 Univariate and multivariate analysis for survival







Prognostic 3 year 5 year P value
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(There were 23 cases of N1, 13 cases of N2, and three
cases N3 patients in hilar cholangiocarcinoma patients.
There were 26 cases of N1, 12 cases of N2 and two cases
N3 patients in distal cholangiocarcinoma patients.)
ExCLNI was identified in 17 of 79 patients (22%) who
had nodal involvement. ExCLNI was identified in 14
cases of distal cholangiocarcinoma (36.8%) and 3 cases
of hilar cholangiocarcinoma (9.8%). The median number
of lymph nodes with ExCLNI was 1 (range 1 to 4).
Correlations between the clinicopathological features
and ExCLNI are presented in Table 2. The presence of
ExCLNI correlated significantly with the distal bile duct
(p= 0.002), although there was no significant difference
in the number of metastatic lymph nodes in patients
with hilar versus distal cholangiocarcinoma (p= 0.746).factor
Age
>70 57 37 0.376
≦70 49 43
Gender
Male 52 38 0.359
Female 56 45Survival and prognostic impact
There was no significant difference in the survival of
patients with hilar versus distal cholangiocarcinoma
(p= 0.105). Three- and 5-year overall survival rates were
53% and 40%, respectively (median follow-up period:
32 month). Nine independent clinico-pathologicalTable 2 Clinicopathological features of significance
ExCLNI
Patients with lymph








Age(years) ≦70 11 33 0.426
>70 6 29
Gender Male 13 40 0.4
Female 4 22
pT Factor T1-2 2 23 0.405
T3-4 15 39
Perineural invasion Present 17 55 0.336
Absent 0 7
Vascular invasion Present 6 11 0.102
Absent 11 55
Tumor location Hilar 3 38 0.002
Distal 14 24






3≧ 9 18 0.086
Seven clinicopathological characteristics of patients with and without ExCLNI
are evaluated. ExCLNI: Extra capsular lymph node involvement. LN: lymph
node.variables were analyzed as possible prognostic factors in-
fluencing survival in patients with ExHBDCs. On uni-
variate analysis, perineural invasion, vascular invasion,
histological grade, and LNM were statistically significant
factors (Table 3). Microscopic margin status did not
show statistically significant differences on survival. On
multivariate analysis, only LNM was identified as a sig-
nificant independent prognostic factor in patients with
resectable ExHBDCs (Table 3).Tumor location
Hilar 50 32 0.105
Distal 57 51
pT factor
pT1/2 66 48 0.002 1.15 (0.84-1.57) 0.387
pT3/4 45 34
Lymph node metastasis
Present 26 14 <0.001 1.82 (1.33-2.47) <0.0001
Absent 68 53
Vascular invasion
Present 30 22 <0.001 1.16 (0.80-1.68) 0.445
Absent 59 44
Perineural invasion
Present 48 33 0.009 1.18 (0.82-1.70) 0.378
Absent 76 64
Histological type
G1 78 63 <0.001 1.27 (0.92-1.76) 0.146
G2/G3/others 43 30
Microscopic margin status
Positive 57 - 0.714
Negative 53 41
Predictive prognostic factors influencing survival: nine independent
clinicopathological variables were analyzed as possible prognostic factors in
patients with ExHBDCs. On univariate analysis, perineural invasion, vascular
invasion, histological grade, and lymph node metastasis were statistically
significant factors. A multivariate analysis was also performed using the above
four factors.
ExHBDCs: extra-hepatic bile duct cancer; pT: 7th classification of AJCC
pathological T factor.
Figure 2 a, Kaplan-Meier (KM) survival curve of patients with
lymph node metastasis (LNM). Patients were divided into two
groups: those with and without extra-capsular lymph node
involvement (ExCLNI). There was no significant difference between
the two groups (p= 0.418). b, Kaplan-Meier (KM) survival curve of
patients with LNM. Patients were divided into two groups according
to location of the LNM (n1, n2, or n3). There was no significant
difference between the groups (p= 0.213). LNM: Lymph node
metastasis c, Kaplan-Meier (KM) survival curve of patients with and
without ExCLNI. Patients were divided into three groups with ≥3
LNM, 2 LNM, or 1 LNM. There was no significant difference between
these groups (p= 0.182). ExCLNI: Extra-capsular lymph node
involvement; LNM: Lymph node metastasis.
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affect survival. The subgroups of LMN including the
presence of ExCLNI, location of the LNM, and the num-
ber of LNM had no statistically significant impact on
survival (Figure 2a, Figure 2b, and Figure 2c). The sub-
groups were also analyzed separately in patients with
hilar cholangiocarcinoma and patients with distal cho-
langiocarcinoma with remarkably similar results (data
not shown).
Discussion
In this study, we showed that ExCLNI was present in
only 22% of the LNM (7% of overall patients) in patients
with surgical treated ExHBDCs. We also revealed that
ExCLNI would have no impact on the survival of
patients with surgically-treated ExHBDCs.
Our data showed that ExCLNI appears less frequently
in patients with resectable ExHBDCs than in patients
with adenocarcinoma of the ampulla of Vater or pancre-
atic cancer (59% and 60%, respectively) [21,22]. One
possible factor may be the anatomic features of
ExHBDCs, especially in hilar cholangiocarcinoma. Our
data showed that incidence of ExCLNI in hilar cholan-
giocarcinoma was significantly lower than the distal
cholangiocarcinoma. Since hilar cholangiocarcinoma
surrounds various complex structures such as the portal
vein, hepatic artery, and the bile duct, more advanced
patients would not have been done operation. Therefore,
incidence of ExCLNI in resectable hilar cholangiocarci-
noma would be very different from that of resectable
distal cholangiocarcinoma. Imre et al. suggested that
tumor location significantly associated with ExCLNI in
patients with laryngeal and hypopharyngeal cancers [31].
Our study seems to support Imre’s findings. But there
seems to be another possible factor, because our data
showed that incidence of ExCLNI in distal cholangiocar-
cinoma was significantly lower than that of previous
reported series of Vater carcinoma (32% vs 59%:
p= 0.030). Certain reason on this difference is still un-
clear. One possible reason will be differences of bio-
logical feature between distal cholangiocarcinoma and
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be that there was also no uniformity in defining ExCLNI
which might make it difficult to compare different stud-
ies. Wind et al. found at least three definitions of the
ExCLNI in the literature [23].
Several authors suggested that ExCLNI reflects cancer
progression, and thus, occurs at an advanced tumor
stage [32-34]. However, our study did not demonstrate a
significant correlation between the occurrences of
ExCLNI and advanced p T stages. Van der Gaag et al.
showed similar results in Vater carcinoma [21]. They
showed that the number of LNM associated with exist-
ence of ExCLNI. Our data showed similar result, even
though our data did not show statistically significant
(p= 0.086). The presence of ExCLNI would reflect not
cancer progression on primary lesion of tumor (size or
depth), but frequency of LNM.
Our data showed that perineural invasion, histological
grade, vascular invasion, and LNM were statistically sig-
nificant prognostic factors in the univariate analysis.
Multivariate analysis showed LNM was an independent
prognostic factor for survival among these prognostic
factors.
A recent report of ExHBDCs revealed that total lymph
node count was correlated with disease specific survival
[6].They revealed adequate total lymph node count
was ≥ 11. In our study, all patients were performed rad-
ical lymphadenectomy: skeletonization of the portal vein
and hepatic artery and with nodal clearance around the
head of pancreas, routinely. Median total lymph nodes
counts resected were 14 in our presented study. There-
fore we thought that our study had enough qualification
to mention about subgroup of LNM in ExHBDCs.
Several authors have adopted the number, location,
and LNR as subgroups of LNM [6,9,11,14-16], and they
showed these subgroups of LNM had prognostic impact
for survival. We thought ExCLNI was also a kind of the
subgroup of LNM, and the present study was the first
report of analyzing the ExCLNI in patients with
ExHBDCs. Our data showed that ExCLNI would not
have prognostic impact for survival.
The differences between many previous studies in
gastrointestinal cancers showed that ExCLNI was asso-
ciated with poor prognosis and our data in ExHBDCs may
be as follows: not only ExCLNI, but also the other sub-
groups such as the number, location of LNM would have
no impact on the survival of patients with ExHBDCs, be-
cause LNM itself would be the most important prognostic
factor in ExHBDCs regardless of any subgroup of LNM.
In hilar cholangiocarcinoma, there is a report suggest-
ing that no correlation exists between the degree of
lymph node metastasis and prognosis, and that the im-
portant factor in determining the prognosis is the pres-
ence or absence of lymph node metastasis [2].A recent report on distal bile duct cancer showed
LNM as an independent prognostic factor but that the
number of LNM had no impact on survival[7]. Japanese
large series of study in distal cholangiocarcinoma also
could not find the significant difference between N1 and
2 (location of LNM) [9].
Two reports regarding both bladder carcinoma and
oral cancer also suggested that ExCLNI had no prognos-
tic impact [35,36]. In the study evaluating bladder car-
cinoma, contradictory results occurred because a certain
percentage of patients received adjuvant chemotherapy
and had a number of lymph nodes removed. In the study
evaluating oral cancer, Greenberg et al. suggested that
the number of LNMs with ExCLNI had an effect on sur-
vival that was unrelated to ExCLNI in and of itself [36].
Conclusion
ExCLNI was detected in 22% of our patients with LNM
in resectable ExHBDCs.
The existence of ExCLNI correlated significantly with
the distal bile duct. The presence of ExCLNI and other
subgroup of LNM would have no impact on their
survival.
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